Amaxa LV Unit for engineered therapeutic cells for regenerative medicine
Biobusiness Grant Recipient: Neil Otto, PhD
Grant Period: 2019-2020
Award Value: $100,000
Site: B-MoGen Biotechnologies
Project Summary: The ultimate goal is to provide our gene transfer transposon/transposase platforms to the rapidly growing field of gene modified cell therapy. B‐MoGen will utilize it’s non‐viral gene transfer technology, Tc Buster, to engineer MSCs and iPSCs as a vehicle to efficiently deliver therapeutic proteins to local sites of inflammation for the regeneration of healthy tissues.